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Solid tumours comprise, not only malignant cells but also a variety of stromal cells and extracellular
matrix proteins. These components interact via an array of signalling pathways to create an adaptable
network that may act to promote or suppress cancer progression. To date, the majority of anti-tumour
chemotherapeutic agents have principally sought to target the cancer cell. Consequently, resistance
develops because of clonal evolution, as a result of selection pressure during tumour expansion. The
concept of activating or inhibiting other cell types within the tumour microenvironment is relatively
novel and has the advantage of targeting cells which are genetically stable and less likely to develop
resistance. This review outlines key players in the stromal tumour microenvironment and discusses
potential targeting strategies that may offer therapeutic beneﬁt.
Focal points:
 Benchside
J The tumour stroma consists of mesenchymal, immune and vascular cells housed in an extracellular
matrix. Stromal cells and extracellular matrix proteins represent genetically stable targets which
can be exploited in cancer treatment. Numerous in vitro and animal studies support the concept of
stromal-directed treatment.
 Bedside
J Several therapeutic strategies have been developed or repurposed to target the stroma. The anti-
angiogenic agent bevacizumab was one of the ﬁrst speciﬁc stromal-targeting agents to be licensed
for cancer treatment over a decade ago. More recently, immune modulation of the stroma has
become a hugely successful strategy, with novel drugs such as checkpoint inhibitors set to re-
volutionise cancer treatment.
 Governments
J Funding bodies should continue to acknowledge the pivotal role that the stroma plays in cancer
progression, in parallel with cancer cell itself. Undoubtedly, the most successful treatment regimens
of the future will address both the “seed” and the “soil”.
& 2016 The Authors. Published by Elsevier Ltd. on behalf of European Society for Translational
Medicine. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).r Ltd. on behalf of European Society for Translational Medicine. This is an open access article under the CC BY license
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Paget [1] ﬁrst highlighted the importance of the tumour mi-
croenvironment (TME) over a century ago when he described his
‘seed and soil’ hypothesis. The concept that cancer cells (seeds)
require a speciﬁc TME (soil) in order to establish or propagate a
tumour is just as valid today and is indeed recognised as the ﬁrst
key milestone, in a series of articles by the journal Nature, high-
lighting the most inﬂuential discoveries in the ﬁeld of cancer [2].
The microenvironment of solid tumours consists of a diverse
network of cellular and acellular components [3]. A histological
categorisation is to divide these elements into cancer and stromal
compartments, with the stromal compartment further divided
into a cellular component and the extracellular matrix. Cancer
cells and cancer stem cells [4] form the cancer compartment.
Stromal cells can be sub-classiﬁed into: mesenchymal (ﬁbroblasts
and mesenchymal stem cells (MSCs)), immune (T cells, macro-
phages, natural killer (NK) cells and antigen presenting cells
(APCs)) and vascular (endothelial cells (ECs) and pericytes). Of
these, vascular cells are permanently located in the TME, immune
cells are transient, and mesenchymal cells may be permanent or
transient [5]. The extracellular matrix (ECM) is a biologically active
three-dimensional scaffold for cancer and stromal cells, compris-
ing proteoglycans and ﬁbrous molecules [6]. By its cellular inter-
actions it permits tumour expansion, invasion and dissemination
[7]. Fig. 1 summarises key components of the TME.
Malignant cells accrue mutations which can allow escape from
regulatory mechanisms [8]. We can think of these cells as ge-
netically unstable and highly plastic [9]. One of the effects of
chemotherapy is to apply selection pressure to these hetero-
geneous cells, allowing expansion of resistant clones. In contrast,
stromal cells are not mutated [10], turnover more slowly [11] and
are therefore genetically more stable. These cells are less likely to
develop chemotherapeutic drug resistance. The stroma is there-
fore an appealing target for novel cancer therapies.
Cancer is characterised by a misregulation of genes such as
those encoding oncogenic, tumour suppressor and DNA repair
proteins [12]. As a result, there are certain key signalling pathways
which are commonly altered across many cancer types, under-
pinning the hallmarks of cancer [13]. Notably, microRNAs (miRs)
are master regulators of gene expression and signalling pathways,
with an estimated one-third of all genes under miR control [14]. As
a consequence, there has been much interest in modulating on-
cogenic and tumour-suppressing miRs for therapeutic beneﬁt.
In this review, we outline existing and potential targets fornovel chemotherapeutic agents in the stroma with an introduction
to miR targeting strategies.2. The mesenchymal stroma
Fibroblasts are mesenchymal cells which secrete ECM compo-
nents [15]. Cancer-associated ﬁbroblasts (CAFs) are variably de-
ﬁned in the literature. It is best to consider them as any ﬁbroblast
adjacent to the tumour, rather than by their expression proﬁle or
cell of origin [16]. CAFs may originate from resident ﬁbroblasts
[17], bone marrow-derived MSCs [18] and epithelial cells (in-
cluding cancer cells and endothelial cells) through the process of
epithelial-mesenchymal transition (EMT; [19],[20],[21]). Spindle
shaped myoﬁbroblasts expressing alpha smooth muscle actin
(αSMA) and vimentin, with typical ultrastructural appearances
[22] are a subpopulation of CAFs which are associated with tu-
morigenesis and cancer progression [23,24] but it is important to
note that not all CAFs are myoﬁbroblasts. Nonetheless, αSMA po-
sitivity is most commonly used to denote the ‘activated’ CAF
phenotype [25] and TGF-β is widely accepted as the main cancer
cell-secreted factor which activates CAFs [26,17].
CAFs, like other ﬁbroblasts, regulate the integrity of the ECM
through their secretory function. In normal physiology, myoﬁ-
broblasts are capable of closing a wound. Cancer is considered to
be a ‘wound that does not heal’ [27] and in this context, myoﬁ-
broblastic CAFs are thought to remain persistently activated [28].
Activated CAFs have been shown to alter the morphology of epi-
thelial cells [29] and drive tumorigenesis [30].
CAFs express the enzyme lysyl oxidase (LOX) and lysyl oxidase-
like proteins (LOX-L) 1–4 which allow crosslinking of ECM sub-
strates such as collagen with elastin. This stiffens the ECM and
stimulates integrin-dependent mechanotransduction pathways
which promote invasion [31]. LOX/LOX-L expression correlates
with worse prognosis in head and neck, lung, ovarian and breast
cancers [32]. LOX inhibitors such as beta-aminopropionitrile
(BAPN) have been shown to reduce breast cancer cell motility in
vitro [33]. In cervical cancer models, the same drug was shown to
reduce hypoxia-induced EMT, invasion and migration [34]. Bon-
dareva et al. [35] showed that BAPN reduced metastasis of MDA-
231 breast cancer cells only if given at the same time or prior to
systemic injection of tumour cells. This suggests that LOX inhibi-
tion is important in preventing extravasation of tumour cells from
the circulation. Nonetheless, this class of drug has not been carried
forward into human trials as yet. Inevitably, with collagen
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Fig. 1. Cellular composition of the tumour microenvironment with relevance to tumour promotion and rejection. APC – antigen presenting cell; ECM – extracellular matrix;
MSC – mesenchymal stem cell; Treg – regulatory T cell; Th – helper T cell; CAF – cancer-associated ﬁbroblast; EC – endothelial cell.
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side effect proﬁle of this kind of drug may be difﬁcult to accept.
The key will be to identify isotypes of the enzyme which are
speciﬁc to CAFs and the TME.
CAFs also play an important role in angiogenesis by secreting
ﬁbroblast growth factor (FGF)-2 [36] as well as vascular en-
dothelial growth factor (VEGF; [37]). The selective dual inhibitor
brivanib targets FGF and VEGF receptors, which is important be-
cause VEGF receptor inhibition alone with bevacizumab has en-
countered chemoresistance [38]. Huynh and colleagues [39]
showed that brivanib reduced tumour size in human xenografts of
hepatocellular carcinoma by increasing apoptosis, and reducing
proliferation and microvessel formation. Phase 2 trials showed
efﬁcacy as ﬁrst [40] and second line (after sorafenib; [41]) treat-
ment in advanced hepatocellular carcinoma. In a randomised
phase 3 trial in patients with unresectable hepatocellular carci-
noma, brivanib improved time to extrahepatic/vascular spread and
time to radiological progression but not overall survival when used
as an adjuvant to trans-arterial chemoembolization [42].
Bone marrow cells are important in determining CAF trans-
differentiation and stromal histology. Systemic endocrine signals
such as osteopontin from tumours recruit particular bone marrow
cells (Sca1þcKit-) into the circulation. The activated bone marrow
cells secrete granulins creating a desmoplastic myoﬁbroblast-
containing stroma around indolent responding tumour cells, sti-
mulating their expansion [43]. Theoretically, inhibiting the acti-
vation of Sca1þcKit cells and or granulin secretion seems ap-
pealing. Unfortunately, this has not materialised into any human
studies which directly target CAFs. As Bateman [44] points out,
Elkabets’ work is contrary to our understanding that removal of
the primary tumour can stimulate development of metastases
from dormant responding cells. Furthermore, selective inhibition
of granulins presents a problem because their cell surface markers
are poorly deﬁned [45].
Another therapeutic strategy is to limit the accumulation of
CAFs in the TME. The anti-ﬁbrotic agent pirfenidone has been
shown to reduce the proliferation of primary pancreatic stellate
cells in vitro. Oral administration of this agent to mice with sub-
cutaneous and orthotopic tumours containing pancreatic cancer
and stellate cells reduced tumour growth and metastasis respec-
tively [46]. This drug, originally purposed for idiopathic pulmonary
ﬁbrosis, is not yet in human trials for cancer but there have been
phase 2 trials in the treatment of neuromas in neuroﬁbromatosis
type 1 [47].Another important cell type in the mesenchymal stroma is the
MSC. These are pluripotent circulating cells which are recruited to
the TME [48]. A signiﬁcant proportion of CAFs are derived from
MSCs [49]. Soluble factors secreted by cancer cells are thought to
promote this transdifferentiation [50]. Karnoub and colleagues
[51] showed that when MSCs are co-injected with weakly meta-
static breast cancer cells in a human xenograft model, it sig-
niﬁcantly increases their metastatic potential. Breast cancer cells
are thought to provoke CCL5 secretion by MSCs, which increases
their own motility, invasion and metastatic potential. Furthermore,
there is evidence to suggest that MSC-derived CCL5 promotes EMT
in a variety of breast cancer cell lines [52]. A similar effect on APS
gastric cancer cells has been observed [53]. The CCR5 receptor
antagonist maraviroc (Celsentri) was shown to reduce the total
body burden of primary and secondary prostate tumours in mice
[54]. Interestingly there is no record of any human study of mar-
aviroc in prostate cancer on the US Clinical Trials database. How-
ever, there has been a single centre phase 1 trial for maraviroc in
colorectal liver metastasis, the results of which are pending
(NCT01736813).3. The immune stroma
Typical immune cells in the TME include T cells, macrophages,
NK cells and APCs. These cells have opposing effects on cancer
progression either through immune surveillance or by allowing
immune tolerance [55]. M1 macrophages, CD8þ cytotoxic T cells,
T helper 1 (Th1) cells, NK cells and APCs have predominantly anti-
tumour effects whereas M2 macrophages, regulatory T cells
(Tregs) and Th2 cells may support tumour progression [56], as
represented in Fig. 1.
CD8þ T cells bind to ‘non-self’ antigens presented by host MHC
class 1 molecules through the T cell receptor, triggering apoptosis
in host cells, including cancer cells [57]. High levels of CD8þ tu-
mour-inﬁltrating lymphocytes (TILs) have been shown to predict
better outcomes in various cancers such as melanoma [58], ovar-
ian [59], colorectal [60], breast [61] and head and neck [62].
Adoptive T cell therapy has been widely studied in the context
of metastatic melanoma. In one of the initial human studies, a
cohort of patients with refractory disease underwent chemother-
apeutic lymphodepletion followed by autologous transfer of ra-
pidly expanded CD8þ T cells. 18 of 35 patients showed objective
clinical and/or radiological responses (3 complete responses) with
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but the expected haematological toxicities were observed. How-
ever, the only patient who was EBV seronegative at recruitment
became seropositive and developed a lymphoma 4 months after
treatment. Importantly, persistence of CD8þ cells after transfusion
determined the degree of efﬁcacy in this study [63]. Genetic
modiﬁcation of T cells to improve tumour reactivity using T cell
receptor [64] and chimeric antigen receptor [65] now offers a
potential cure to patients with metastatic melanoma. The chal-
lenge now is to translate these approaches to other cancer types.
Adoptive T cell therapy has been reviewed extensively elsewhere
[66,67]. We now focus on other T cell targets.
Tregs are CD4þ/CD25þ T cells speciﬁcally expressing FoxP3
which are capable of suppressing the effects of other immune cells
[68,69]. Several studies have shown that high numbers of in-
tratumoral Tregs are associated with advanced stage or recurrence
in various malignancies including ovarian [70], breast [71], oeso-
phagogastric [72] and liver [73]. Speciﬁc targeting of Tregs has
shown promise in animal and early human studies. Mice bearing a
renal cell carcinoma were given anti-CD25 monoclonal antibody
against Tregs and inoculated with pre-primed CD8þT cells. At day
50, tumours were undetectable in all the mice. In contrast, un-
treated mice, or mice treated with either CD8þ T cells or anti-
CD25 did not survive [74]. Rech et al. [75] repurposed the anti-
CD25 monoclonal antibody daclizumab (FDA-approved for pro-
phylaxis of organ rejection) to the same effect. As well as down-
regulating Tregs, daclizumab was shown to reprogramme them to
express the pro-inﬂammatory cytokine interferon-γ (IFN-γ). In a
small phase 1 study of metastatic breast cancer patients, daclizu-
mab reduced Treg numbers within 1 week, a phenomenon which
lasted for at least 7 weeks. Samples from all evaluable patients
showed greater CD8þT cell response to at least one tumour an-
tigen (hTERT peptide) after daclizumab treatment and vaccination.
However, when comparing cohorts who received daclizumab plus
vaccination or vaccination alone, although immune response rate
and overall survival was greater in the combination cohort, this
was not statistically signiﬁcant.
The PI3K–AKT pathway is an important regulator of Treg ac-
tivity. Selective inhibition of the PI3Kδ isoform has been shown to
repress AKT activation and proliferation of Tregs in vitro and in vivo
in a TC-1 tumour model [76]. More comprehensively, Ali et al. [77]
knocked down PI3Kδ in mice and showed reduction in primary
tumour growth in melanoma, lung, thymoma and breast xeno-
grafts and reduction of metastasis when 4T-1 breast cancer cells
were injected systemically. Knockdown mice had reduced num-
bers of Tregs in draining lymph nodes when injected with 4T-1
cells and allogenic Treg transfer from one knockdown animal to
another upregulated intratumoral CD8þ T cells in the thymoma
model. Furthermore, pharmacological inhibition of PI3Kδ with PI-
3065 had similar effects to knockdown in the breast cancer model
and improved survival in a pancreatic cancer model. Interestingly,
idelalisib, the PI3Kδ inhibitor has been approved for the treatment
of B cell malignancies [78,79,80] but not necessarily with the in-
tention of modulating Tregs.
Immune checkpoints are important regulators of CD8þ and
Treg cell activity. In the cancer setting, a vast number of new
antigens are generated. To prevent autoimmunity, immune
checkpoints are activated to dampen pro-inﬂammatory T cell
responses, at the cost of allowing immune escape of cancer cells
[81]. The most well known immune checkpoints are cytotoxic T
lymphocyte-associated protein-4 (CTLA-4) and programmed cell
death protein-1 (PD-1). CTLA-4 mainly prevents co-stimulation
of the CD28 receptor [82] and represses early activation of
CD8þ T cells in lymphoid tissues. PD-1 attenuates CD8þ T cell
activity in peripheral tissues [83] such as the TME. Both CTLA-4
and PD-1 promote Treg development and activity [84]. Theintroduction of immune checkpoint inhibitors in the treatment
of metastatic melanoma has been greeted with a great deal of
enthusiasm. An important phase 3 trial of advanced melanoma
patients showed that the CTLA-4 inhibitor ipilimumab sig-
niﬁcantly improved overall survival with or without co-admin-
istration of the melanoma antigen gp100 [85]. In a more recent
randomised controlled trial, the PD-1 inhibitor nivolumab, as
monotherapy or in combination with ipilimumab, effectively
improved progression-free survival compared to ipilimumab
monotherapy. As expected in patients with PD-1 ligand negative
tumours, combination therapy was more effective than mono-
therapy [86]. Similarly, targeting the PD-1 ligand (PD-L1) with
the monoclonal antibody atezolizumab has proved efﬁcacious
with tolerable side effects in a phase 1 trial of metastatic mel-
anoma, non-small cell lung cancer (NSCLC) and renal cell cancer,
in patients with tumours expressing high total and high CD8þ T
cell levels of PD-L1 [87]. Similar results were seen in a phase
1 trial of metastatic urothelial bladder cancer [88]. This drug is
now in phase 2 studies for metastatic NSCLC (e.g. POPLAR trial
[89]). Additionally, mismatch repair deﬁciency is associated
with a high somatic mutational burden. This generates greater
numbers of neoantigens, necessitating enhanced checkpoint
inhibition. Le et al. [90] conducted a phase 2 trial of the PD-1
inhibitor pembrolizumab (FDA-approved for melanoma and
NSCLC [91],[92]) in patients with mismatch repair deﬁcient and
proﬁcient metastatic cancers, with a focus on colorectal cancer.
Patients with mismatch repair deﬁcient tumours responded
better to PD-1 inhibition, providing proof of principle for this
concept.
Th cell subtypes have antagonistic effects on cancer progres-
sion. Th1 cells activate cytotoxic CD8þ T cells and have been
shown to mediate tumour regression in a murine pulmonary ﬁ-
brosarcoma model [93]. In murine B cell lymphoma and myeloma
models of successful immunosurveillance, Th1-associated cyto-
kines (IL2, IL12 and IFN-γ) were consistently identiﬁed in im-
planted tumour-Matrigel plugs [94]. In contrast, Th2 cells are in-
volved in immune tolerance and have been shown to be markers
of active [95] and advanced [96] disease. There may be a role for
Th2 cells in prognostication.
In terms of macrophages, classical M1 polarisation (IL-12highIL-
10low) is associated with expression of pro-inﬂammatory cytokines
and tumour rejection, whereas alternative M2 polarisation (IL-
12lowIL-10high) is associated with tumour progression [97,98]. Tu-
mour-associated macrophages (TAMs) are a mixed population of
M1 and M2 cells, although some [99] suggest that they generally
possess the M2 phenotype because they are incapable of activating
sufﬁcient nitric oxide and pro-inﬂammatory cytokine responses to
tumour cells [100]. Furthermore, TAMS are associated with Treg
activation [70], PD-L1-mediated checkpoint activation [101], an-
giogenesis [102] and invasion [103]. Many studies have shown that
stromal TAMs predict poor prognosis in cancers such as lung [104],
endometrial [105], thyroid [106] and breast [107]. Indeed, a recent
meta-analysis of stromal TAMs in cancer prognosis showed
worse overall survival in gastric, urogenital and head and neck
cancers but surprisingly, a better overall survival in colorectal
cancer [108].
In order to selectively target TAMs, Luo et al. [109] produced a
DNA vaccine against legumain, a stress protein which TAMs
overexpress. In the prophylactic group, pulmonary metastases
from intravenously injected breast, colon and NSCLC cells were
signiﬁcantly reduced following vaccination. In the therapeutic
group, overall survival was signiﬁcantly better if animals were
vaccinated after orthotopic injection of breast cancer cells. The
survival of TAMs is dependent on colony stimulating factor re-
ceptor-1 (CSFR-1). Ries and colleagues [110] blocked CSFR-1 di-
merisation with a novel monoclonal antibody InRG7155
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this led to reduction of TAMs with an associated increase in CD8þ
T cells and was associated with less tumour growth in animal
models of colorectal cancer and ﬁbrosarcoma. In a small phase
1 study, administration of this agent effected at least a partial
metabolic response in all 7 patients with diffuse-type giant cell
tumour. More recently, Cassier et al. [111] reported an objective
response in 24 of 28 patients with grade 3 adverse events in 5 of
25 patients.
NK cells are innate to the immune system and are able to
directly kill tumour cells in several different in vitro cancer
models [5]. NK cells express the death ligands FasL and TRAIL
which bind to Fas and DR5 receptors on target cells to trigger
apoptosis [112]. Alternatively, NK cells express CD16 which
mediates antibody dependent cell-mediated cytotoxicity
[113,114]. However, MHC class 1 molecules on tumour cells are
able to bind killer inhibitory receptors on NK cells to dampen
their cytotoxic effects [115]. This suggests that cytotoxic T cell
activation is at the expense of NK activity. Nonetheless, NK cell
immunotherapy has been popular in several recent human
studies, the majority of which concern haematological malig-
nancies (summarised in [116]). Different methods of enhancing
NK activity include in vivo cytokine stimulation and adoptive
transfer of ex vivo-stimulated autologous, allogenic or NK cell
lines. Early phase 2 studies used IL-2 to stimulate resident NK
cells and proved to be effective in metastatic melanoma [117]
and metastatic renal cell carcinoma [118]. However, this was
associated with severe side effects including sepsis-related
mortality. In terms of adoptive therapy, Ishikawa et al. [119]
conducted a small phase 1 study with malignant gliomas. Per-
ipheral blood mononuclear cells (PBMCs) were isolated from
each patient and NK cells were expanded ex vivo using IL-2.
Autologous NK cells were then injected into the tumour cavity
and/or intravenously in a total of 16 courses. MRI showed partial
responses after 3 of the 16 courses. Importantly, there were no
signiﬁcant neurological side effects. Another phase 1 study in
patients with NSCLC used allogenic NK cells from donor re-
latives, expanded ex vivo with IL-15 and hydrocortisone. There
was partial response in 2 of 16 patients and disease stabilisation
in 6 patients. Again, there were no major local or systemic side
effects [120]. Infusion of the cell line NK-92 has also proved to
be well tolerated in patients with a range of advanced malig-
nancies with a persistence of at least 48 h [121]. The require-
ment to generate large numbers of NK cells for immunotherapy
has now driven research into NK cell production from em-
bryonic stem cells [122].
APCs process foreign antigens and present them alongside
MHC class 1 or 2 molecules to naïve CD8þ and Th cells re-
spectively. Professional APCs such as dendritic cells, macro-
phages and B cells are so named because they process and
present antigens most effectively [123]. In terms of cancer
therapy, APCs have been used to improve the efﬁcacy of adop-
tive T cell transfer. The ideal adoptive treatment will use T cells
which proliferate, persist, target and destroy tumour cells [124].
Autologous and artiﬁcial APCs have been used to this effect,
however the use of autologous APCs is cumbersome and time
consuming [125]. Artiﬁcial APCs have been generated using
Drosophila cells [126], murine ﬁbroblasts [127] and K562 hu-
man leukaemic cells [128]. The overarching principle is to pro-
duce a cell which expresses restricted HLA antigens in combi-
nation with transfected co-stimulatory molecules such as ICAM-
1 (CD54) and B7.1 (CD80). Alternatively, magnetic beads em-
bedded with HLA antigens [129] and HLA expressing extra-
cellular vesicles [130] have been employed instead of feeder
cells in the experimental setting. More recently, Butler and
colleagues [131] transfected K562 cells with HLA-A2, CD80 andCD83 to produce aAPC-A2 cells, from which they selected a
single clone. This clone was used to expand autologous MART-1
speciﬁc CD8þ T cells from PBMCs ex vivo. The MART-1 T cells
were then given to 9 patients with advanced melanoma in a
total of 17 infusions. This therapy has the beneﬁt of not re-
quiring lymphodepletion or IL-2 treatment and consequently
there were no severe adverse effects. One patient had a com-
plete metabolic response which lasted 54 months and 4 others
had stabilisation of disease to at least day 70.4. The vascular stroma
The tumour vasculature consists of ECs and pericytes. ECs form
stromal capillaries and pericytes provide structural support. In
healthy tissue, pericytes intimately cover ECs and through the
expression of VEGF and angiopoetin-1 they lead to increased EC
survival and structural stabilisation [132]. Reciprocally, ECs express
platelet-derived growth factor-β (PDGF-β) and recruit pericytes
from the stroma [133]. In the TME, tissue hypoxia and the con-
sequent upregulation of pro-angiogenic factors such as VEGF and
angiopoetins has the effect of loosening the connections between
pericytes and ECs [134]. Ultimately, pericytes detach completely
and this allows a disordered budding of new capillaries which
underlies angiogenesis [135]. PDGF receptor antagonists targeting
pericytes have been shown to stunt growth of end stage pancreatic
islet cell tumours in mice [136]. However, the beneﬁcial effect on
the primary lesion seems to be at a cost. The Kalluri group has
shown that inhibiting pericytes in an invasive breast cancer model
has two detrimental effects: ﬁrstly it reduces pericyte coverage of
ECs which correlates directly with metastasis; secondly, it ag-
gravates tissue hypoxia which drives the EMT/mesenchymal–epi-
thelial transition cascade [137]. Given this evidence, it seems
prudent not to target pericytes but to focus on their downstream
angiogenic signals.
It is well established that hypoxia develops as a tumour ex-
pands and that its size is limited without neovascularisation or
angiogenesis. Folkman et al. [138] ﬁrst reported that a soluble
factor, now known as VEGF, was responsible for angiogenesis.
VEGF is released by pericytes and binds to VEGF receptors on ECs
which become the “tip” of a sprouting chain. The “tip” migrates
towards the highest VEGF concentration which is present in the
most hypoxic regions of the TME. ECs which lie behind the “tip”
bind to each other through surface ligand-receptor interactions
and form a new capillary [139].
Several monoclonal antibodies have been developed to target
VEGF-driven angiogensis. Bevacizumab, targeting VEGF-A, is the
most well known amongst these. It received US FDA approval in
2004 for use in metastatic colorectal cancer in combination with
standard chemotherapy [140]. Since then it has been used in ad-
vanced NSCLC [141], renal, ovarian [144] and cervical [145] can-
cers, supported by evidence from large phase 3 studies. However,
there are a certain group of patients who do not respond to
treatment or develop resistance [146]. Fan et al. [147] showed that
long term exposure (3 months) of colorectal cancer cell lines to
bevacizumab led to increased expression of VEGF-A,B and C, in-
creased phosphorylation of VEGF-1 and 2 receptors, increased
invasion and migration and increased metastasis when injected
into an in vivo model. Moreover, VEGF inhibition has mostly had
clinical success in combination with traditional chemotherapy,
possibly because it normalises stromal vessels and allows better
drug delivery [148]. Nonetheless, anti-VEGF agents are still being
developed. For example, the VEGF-2 receptor monoclonal anti-
body ramucirumab is licensed for use in advanced gastric cancer
after phase 3 trials showed survival beneﬁt as a single therapy
(REGARD trial [149]) and in combination with paclitaxel
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Another class of anti-angiogenic drugs are the VEGF/PDGF-re-
ceptor tyrosine kinase inhibitors which have shown signiﬁcant re-
sponse in several phase 3 trials. These drugs inhibit tyrosine kinase
receptors from activating intracellular serine/threonine kinases such
as Raf, resulting in reduced proliferation and angiogenesis [151].
Sorafenib is an oral multikinase inhibitor which is approved for use
as monotherapy in advanced renal cell, hepatocellular and thyroid
carcinomas. The ﬁrst large phase 3 study of sorafenib monotherapy
in 2007 showed increased progression free survival compared to
placebo in advanced renal cell carcinoma [142,143]. However, there
was signiﬁcantly more hypertension and angina in the treatment
arm. Another randomised controlled trial showed an increase in
overall survival and time to radiological progression in advanced
hepatocellular carcinoma patients [152]. Most recently, an increase in
progression free survival has been shown in radioactive iodine-re-
fractory differentiated thyroid cancer [153].
Whereas anti-angiogenic drugs target new vessel formation,
vascular damaging agents (VDAs) target existing vessels, caus-
ing ischaemia and haemorrhagic necrosis of the tumour [154].
There are two classes of VDAs: small molecule microtubule
targeting drugs and ligand based drugs. Small molecule agents
exploit differences between tumour and normal vessels such as
greater proliferation and reliance on a cytoskeleton. Ligand
based drugs target proteins such as VEGF-receptors which are
overexpressed in tumour vessels [155]. Combretastatin A4
phosphate (CA4P) or fosbretabulin, is an example of a small
molecule VDA. CA4P binds to tubulin causing microtubule de-
polymerisation [156]. CA4P has reached phase 2 studies for
advanced anaplastic thyroid carcinoma where there was poor
efﬁcacy [157] and relapsed ovarian carcinoma where signiﬁcant
clinical responses deemed suitable an extension to the trial
[158]. These studies corroborated phase 1 trial safety data sug-
gesting that it is a safe drug overall with common severe side
effects of neuropathy and tumour pain.
An interesting ligand based approach is to fuse toxins to stro-
mal vascular ligands. Rosenblum's group constructed the fusion
molecule VEGF(121)/rGel which combines a VEGF ligand with the
plant toxin gelonin [159]. This has shown promise in reducing
tumour growth in animal models of bladder [159], metastatic
breast [160] and metastatic prostate cancer [161]. Drugs of this
class are yet to make clinical trials.
Reduced oxygen tension in the TME leads to upregulation of
hypoxia inducible factors (HIFs) by ECs [162]. HIF-1 regulates EC
proliferation [163] and HIF-2 causes EC senescence [164]. Branco-
Price and colleagues [165] showed that there was slower migra-
tion of tumour cells through HIF-1α deﬁcient EC layers and re-
duced metastasis in HIF-1α deﬁcient mice. HIF-2α deletion has the
opposite effects. Consequently, digoxin has been found to inhibit
HIF-1α ([166]). It is currently in a phase 2 study which aims to
assess tissue HIF1α levels in resected breast cancers after 2 weeks
of digoxin pre-treatment (NCT01763931).5. ECM
The ECM is comprised of proteoglycans such as hyaluronan
and versican and ﬁbrous proteins such as collagen, elastin, ﬁ-
bronectin, laminin, periostin and tenascin-C [167,168]. It is
biologically active and plays a role in cellular adhesion, migra-
tion, proliferation and survival [169]. ECM composition varies
between tissues. In the cancer setting, ﬁbroblasts express vast
amounts of ECM proteins leading to tissue stiffening [7]. Stif-
fening is exacerbated by LOX-mediated collagen crosslinking as
described above [31]. Paszek and colleagues [170] suggest that
matrix stiffness is an exogenous force whilst Rho-dependentcytoskeletal tension is an endogenous force on cancer cells. The
summation of these forces results in clustering of integrins and
activation of ERK and ROCK signalling which leads to increased
proliferation and contractility respectively. The pro-in-
ﬂammatory reaction in the TME triggers myoﬁbroblast trans-
differentiation which adds to ﬁbrosis or desmoplasia [171].
Desmoplasia has been associated with poor prognosis in cancer
for over 20 years [172]. Additionally, matrix metalloproteases
(MMPs) are expressed by stromal and epithelial cells and re-
model the ECM, particularly the basement membrane and po-
tentiate release of growth factors such as VEGF [173]. Clearly
then, the combined ECM effects of stiffness, reciprocal con-
tractility, desmoplasia and MMP activity are important in tu-
morigenesis and cancer progression. Below we outline some key
ECM targets.
Hyaluronan is associated with a permissive TME [174]. The
dense hyaluronan matrix surrounding cancer cells makes it difﬁ-
cult for chemotherapeutic drugs to penetrate. This is a particular
problem for monoclonal antibody therapy because it prevents
antibody directed cell-mediated cytotoxicity by NK cells. Singha
et al. [175] showed that co-administration of recombinant hya-
luronidase with the monoclonal antibody traztuzumab and NK
cells signiﬁcantly reduced tumour growth in ovarian cancer xe-
nografts. Recombinant hyaluronidase (PEGPH20) has been suc-
cessfully proﬁled for safety in phase 1 trials in advanced pancreatic
cancer [176]. There is currently an ongoing phase 2 trial of
PEGPH20 in untreated stage 4 pancreatic carcinoma in combina-
tion with paclitaxel and gemcitabine (NCT01839487).
The matricellular protein periostin is a ligand for αvβ3 and αvβ5
integrins on epithelial cells, promoting cell motility [177]. Under-
wood et al. [178] showed that periostin is associated with poor
overall survival and disease-free survival in oesophageal adeno-
carcinoma. Additionally, periostin was shown to be secreted by
CAFs and had the effect of activating the AKT survival pathway in
oesophageal cancer cells. Periostin is also upregulated in colorectal
primary and secondary tumours [179]. In vitro, periostin was
shown to directly increase proliferation of several colorectal can-
cer cell lines. This effect was attenuated by addition of a periostin-
speciﬁc antibody which triggered cancer cell apoptosis and
worked synergistically with 5FU. Animal studies have shown that
MZ-1, a monoclonal antibody to periostin, can reduce growth and
metastatic potential of A2780 ovarian cancer xenografts [180].
Currently there are no ongoing clinical studies of anti-periostin
therapy.
Decorin was shown to be differentially expressed in the tumour
mass of malignant angiosarcomas compared to benign hae-
mangiomas [181]. Grant et al. [182] transfected sarcoma and car-
cinoma cell lines with decorin. These cells produced signiﬁcantly
less VEGF than their wild type counterparts. Conditioned media
from the transfected cells reduced EC attachment, migration and
differentiation. In vivo, decorin transfected xenografts were smal-
ler and showed less neovascularisation. Recently, Xu et al. [183]
created an oncolytic adenovirus carrying the decorin gene (Ad.
dcn) which signiﬁcantly reduced bony metastases in a murine
prostate cancer model. Decorin manipulation has not matured into
a useable therapy as yet.
Tenascin-C is preferentially expressed by various tumours
[184]. Monoclonal antibody therapy with 81C6 has reached phase
2 trials in patients with malignant gliomas showing favourable
efﬁcacy when compared to brachytherapy or radiosurgery [185]. In
this study, 33 patients had injection of radioiodine-labelled 81C6
to cerebral resection cavities followed by standard chemor-
adiotherapy. Median survival was better in this cohort than in
historical controls receiving standard treatment. However, 9 pa-
tients developed haematological toxicity and 5 patients had neu-
rological toxicity. Consequently, this drug has not featured in
R. Bhome et al. / New Horizons in Translational Medicine 3 (2016) 9–21 15phase 3 studies. An alternative to antibody therapy is the use of
RNA interference (RNAi) to downregulate tenascin-C. In one study,
double stranded RNA targeting tenascin-C (ATN-RNA) was injected
into the resection cavities of 46 patients with malignant brain
neoplasms. This treatment showed survival beneﬁt in astro-
cytomas and glioblastomas [186].6. MiR signalling in the TME
MiRs are small (20–30 nucleotide) non-coding RNAs which
repress protein translation by binding to the 3’ UTR region of
mRNAs [187]. Several physiological processes such as proliferation,
differentiation and apoptosis are regulated by miRs [188]. De-
regulated miRs can lead to tumorigenesis [189]. There has been a
great deal of interest in deregulated miRs as biomarkers in diag-
nosis, tumour subtyping, prognosis and response to treatment.
MiR-21 overexpression is associated with breast, hepatocellular
and colorectal carcinoma for example [190]. MiR-21 represses tu-
mour suppressor proteins such as PDCD4 and PTEN [191]. We have
shown by laser capture microdissection that miR-21 is a stromal
rather than epithelial signal in colorectal tumours. Indeed, co-in-
jection of miR-21 overexpressing ﬁbroblasts with DLD-1 colorectal
cancer cells leads to increased metastasis in an orthotopic murine
model [192]. To explain this phenomenon, it is possible that miR-
21 is shuttled from ﬁbroblasts to cancer cells. This is supported by
evidence that RNAs can be transferred between cells in extra-
cellular vesicles [193].
There are several observational studies assessing miR proﬁles
in different malignancies. One systematic review of over 40 studies
highlighted total (stromal and epithelial) tumoral miR-21 over-
expression and let-7 downregulation as key determinants of pa-
tient outcome [194]. Indeed, we have shown that stromal miR-21
predicts poor disease free survival and overall survival in stage II
(node negative, metastasis negative) colorectal cancer [195].
This is important because it may help to distinguish those stage II
patients who require adjuvant chemotherapy from those who do
not.
In terms of miR-based cancer therapy, the miR-34a mimic
MRX34 is currently in a phase 1 trial for patients with un-
resectable, advanced or metastatic hepatocellular carcinoma
which is due to complete in 2016 (NCT01829971). MiR-34 is a
tumour suppressor which is thought to oppose proliferation, mi-
gration and chemoresistance [196]. MRX34 uses a liposomal de-
livery system which allows the drug to accumulate in the liver
[197]. There are no other miR based cancer therapies in human
trials at present, however the miR-122 antagonist Miravirsen for
hepatitis C is in late phase 2 trials [198]. Similarly, the anti-miR-21
agent RG-012 (Regulus Therapeutics) has received orphan drug
status from the US FDA and European Commission and is in a
phase 1 trial for the treatment of renal ﬁbrosis in Alport's
syndrome.
Table 1 summarises the key experimental and clinical studies
which have led to the development and approval of stromal-di-
rected therapies in solid tumours.7. Conclusion
For a long time, Paget's theories about the “soil” remained in the
shade and ignored. In recent years however, there has been a focus
of research efforts in this ﬁeld, simultaneously bringing to light a
variety of stromal-directed therapeutic strategies. The great appeal
of the stromal TME is its genetic stability and reduced likelihood of
Darwinian emergence of resistance, as seen in cancer cells.
Moreover, stromal-directed therapy offers two key beneﬁts: ﬁrstly,it creates an arid “soil” making it more difﬁcult for a tumour to
establish at both primary and secondary sites; consequently, it
reduces the required doses of traditional cytotoxic chemother-
apeutic drugs. With this in mind, the future of cancer therapy
looks promising. The ultimate treatment regimens will include
interventions which manipulate each component of the TME, in
both stromal and cancer compartments, to promote tumour re-
jection. Ideally, these regimens will be personalised for each in-
dividual depending on the cellular and molecular ﬁngerprint of
their TME. This is not unrealistic if we consider that adoptive
immune cell therapy, which epitomises personalised cancer
treatment, is already well established.
In this review, we have highlighted key cellular and molecular
targets within the stromal TME and summarised relevant pre-
clinical and clinical data associated with each. The article provides
up to date, structured and comprehensible information on the
translational aspects of stromal cancer therapy and how it has
evolved from bench to bedside.Executive summary The TME is a functional ecosystem of cancer cells and stroma
which interact through an array of signalling molecules. The
stroma consists of mesenchymal, immune and vascular cells
together with the ECM.
 In comparison to cancer cells the stroma is genetically stable
and therefore, anti-stromal therapies are less likely to succumb
to chemoresistance.
 There is huge excitement about redirecting and modulating the
immune stroma to reject a tumour with the most successful
approaches being adoptive T cell therapy and immune check-
point inhibition respectively.
 Targeting the vascular stroma with anti-VEGF agents is asso-
ciated with intrinsic resistance. This has accelerated FDA ap-
proval of alternative anti-angiogenic agents such as sorafenib
and prompted the development of mechanistically different
drugs (VDAs).
 The mesenchymal stroma and ECM are equally important in
cancer progression but therapies speciﬁcally targeting CAFs,
MSCs and ECM proteins are fewer and in comparatively earlier
stages of development.
 MiRs are master controllers of gene expression which are de-
regulated in cancer. MiR proﬁling has been shown to be useful
in cancer prognostication. MiR modulating therapies are now in
early human trials.Ethical statement
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Table 1
Stromal targeting therapies in solid tumours: a summary of relevant clinical and pre-clinical studies. CAF – cancer-associated ﬁbroblast; LOX – lysyl oxidase; BAPN – beta-aminopropionitrile; FGF – ﬁbroblast growth factor; VEGF –
vascular endothelial growth factor; MSC – mesenchymal stem cell; TCR – T cell receptor; CAR – chimeric antigen receptor; PD-1 – programmed cell death protein-1; CTLA4 – cytotoxic T lymphocyte associated protein-4; NSCLC –
non-small cell lung cancer; PD-L1 – PD-1 ligand; Treg – regulatory T cell; mAb – monoclonal antibody; TAM – tumour-associated macrophage; CSFR1 – colony stimulating factor-1; APC – antigen presenting cell; EC – endothelial cell;
GOJ – gastro-oesophageal junction; PDGF – platelet-derived growth factor; VDA – vascular disrupting agent; HIF – hypoxia inducible factor; ECM – extracellular matrix; miR – microRNA.
Stromal compartment Target cell/
molecule
Drug/therapy Mechanism of action Level of
evidence
Cancer type US FDA approval Key reference(s)
Mesenchymal CAF BAPN LOX inhibitor Pre-clinical Breast [31,35]
Brivanib FGF/VEGF receptor
antagonist
Phase 3 Hepatocellular [42]
Pirfenidone Antiﬁbrotic Pre-clinical Pancreatic [46]
MSC Maraviroc CCR5 antagonist Phase 1 Colorectal NCT01736813 (clinicaltrials.gov)
Immune CD8þ T cell Autologous T cells Adoptive T cell Phase 2 Melanoma [63]
TCR T cells Adoptive T cell Phase 1/2 Melanoma [64]
CAR T cells Adoptive T cell Pre-clinical Melanoma [65]
Nivolumab PD-1 inhibitor Phase 3 Melanoma Yes [86]
Pembrolizumab PD-1 inhibitor Phase 2/3 Mismatch repair deﬁcient tumours;
Melanoma; NSCLC
Yes (melanoma;
NSCLC)
[90,91,92]
Ipilimumab CTLA-4 inhibitor Phase 3 Melanoma Yes [85]
Atezolizumab PD-L1 inhibitor Phase 2 NSCLC [89]
Treg Daclizumab CD25 mAb Phase 1 Breast [75]
PI-3065 PI3Kδ inhibitor Pre-clinical Breast; Pancreatic [77]
TAM Emactuzumab CSFR1 antagonist Phase 1 Diffuse type giant cell tumour [111]
NK Cell IL-2 Resident NK stimulation Phase 2 Melanoma; renal [117,118]
Autologous NK cells Adoptive NK cell Phase 1 Glioma [119]
Allogenic NK-92 cells Adoptive NK cell Phase 1 Various [121]
APC Artiﬁcial aAPC-A2 cells MART-1 T cell generation Phase 1 Melanoma [131]
Vascular EC/Pericyte Bevacizumab VEGF receptor antagonist Phase 3 Colorectal; NSCLC; renal; ovarian;
cervical
Yes (all) [140,141,144,145]
Ramucirumab VEGF receptor antagonist Phase 3 Gastric; GOJ Yes (gastric; GOJ) [149,150]
Sorafenib VEGF/PDGF receptor
inhibitor
Phase 3 Renal; hepatocellular; thyroid Yes (all) [142,152,153]
Fosbretabulin Small molecule VDA Phase 2 Thyroid; Ovarian [157,158]
VEGF(121)/rGel Ligand-based VDA Pre-clinical Bladder; Breast; Prostate [159,160,161]
Digoxin HIF-1 alpha inhibitor Phase 2 Breast NCT01763931 (clinicaltrials.gov)
Pericyte SU6668 PDGF receptor antagonist Pre-clinical Pancreatic [136]
ECM Hyaluronan PEGPH20 Recombinant
hyaluronidase
Phase 1b/2 Pancreatic [176]; NCT01839487 (clincaltrials.
gov)
Periostin MZ-1 Periostin mAb Pre-clinical Ovarian [180]
Decorin Ad.dcn Oncolytic virus Pre-clinical Prostate [183]
Tenascin-C 81C6 Tenascin-C mAb Phase 2 Glioma [185]
ATN-RNA RNA interference Phase 1 Glioma [186]
MiR MiR-34 MRX34 MiR-34 mimic Phase 1 Hepatocellular NCT01829971 (clinicaltrials.gov)
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